Starling Oncology, Inc. (STLN) earnings date
Mar 18, 2027, after close estimated
Estimated from the company's SEC filing cadence. The company has not confirmed it. Companies usually announce two to four weeks ahead.
- Fiscal period
- Q4 FY2026
- Confidence
- 10% chance of landing within a day
- Source
- Filing history on EDGAR
- Last checked
- 2026-11-18
Read by software from public filings and company announcements. Can be wrong. Verify with the company or the SEC. Not investment advice.
How this company behaves
| Announces its report date | Not enough announcements on file yet to say |
| Reports after the quarter ends | 44 days, typically, give or take 18 (last 8 releases) |
Last 8 releases
| Period | Released | Timing | Days after period end | Filing |
|---|---|---|---|---|
| Q3 FY2026 | Thu, Nov 5, 2026 | after close | 36 | 8-K |
| Q2 FY2026 | Thu, Aug 6, 2026 | after close | 37 | 8-K |
| Q1 FY2026 | Thu, May 7, 2026 | after close | 37 | 8-K |
| Q4 FY2025 | Thu, Mar 12, 2026 | after close | 71 | 8-K |
| Q3 FY2025 | Thu, Nov 13, 2025 | after close | 44 | 8-K |
| Q2 FY2025 | Wed, Aug 13, 2025 | after close | 44 | 8-K |
| Q1 FY2025 | Wed, May 14, 2025 | after close | 44 | 8-K |
| Q4 FY2024 | Mon, Mar 24, 2025 | before open | 83 | 8-K |
What they guided beta
| Q3 FY2026 | "Starling Oncology Reports Third Quarter 2026 Financial Results and Updates Full-Year 2026 Guidance" exhibit |
| Q3 FY2026 | "CERRITOS, Calif., November 5, 2026 -- Starling Oncology, Inc. (NASDAQ: STLN) (“STLN” or the “Company”), one of the largest value-based community oncology groups in the United States, today reported financial results for its quarter ended September 30, 2026 and updated it's full-year 2026 guidance." exhibit |
| Q3 FY2026 | "Daniel Virnich, CEO of Starling, commented, "The third quarter of 2026 was another strong quarter for our company, with revenue up 24% year over year and Adjusted EBITDA of $3.4 million, our second consecutive quarter of positive Adjusted EBITDA and above our third quarter outlook of $0.50 million to $1.5 million." exhibit |
| Q3 FY2026 | "Based on our performance year to date, we are affirming our full-year 2026 guidance, and we believe we are well positioned for continued growth into 2027."" exhibit |
| Q3 FY2026 | "Fourth Quarter of 2026 Outlook" exhibit |
| Q2 FY2026 | "Starling Oncology Reports Second Quarter 2026 Financial Results and Updates Full-Year 2026 Guidance" exhibit |
| Q2 FY2026 | "CERRITOS, Calif., August 6, 2026 -- Starling Oncology, Inc. (NASDAQ: STLN) (“STLN” or the “Company”), one of the largest value-based community oncology groups in the United States, today reported financial results for its quarter ended June 30, 2026 and updated it's full-year 2026 guidance." exhibit |
| Q2 FY2026 | "Updated Outlook for Fiscal Year 2026" exhibit |
| Q2 FY2026 | "2026 Guidance - Previous 2026 Guidance - Updated" exhibit |
| Q2 FY2026 | "The Company expects approximately $150 million in capitated revenue in 2026." exhibit |
Get this as JSON
curl -H "X-API-Key: vt_live_..." https://api.veritasdata.dev/v1/next/STLN
# how far back the record goes for this company
curl -H "X-API-Key: vt_live_..." https://api.veritasdata.dev/v1/coverage/STLN
Put this date on your page
A badge that stays current. It links back to this page and needs no key. Embed it unmodified, with its link to this page intact: the badge is too small to carry the notice below, so the page it links to does.
Read by software from public filings and company announcements. Can be wrong. Verify with the company or the SEC. Not investment advice.
HTML
<a href="https://veritasdata.dev/company/STLN/"><img src="https://veritasdata.dev/embed/STLN.svg" alt="STLN earnings date" width="240" height="56"></a>
Markdown
[](https://veritasdata.dev/company/STLN/)
Script
<script async src="https://veritasdata.dev/embed/STLN.js"></script>
Get a free key: 100 calls, every company
Sign in with GitHub or Google. The key works on every endpoint and in the MCP server.
curl -H "X-API-Key: vt_live_..." "https://api.veritasdata.dev/v1/next/STLN"
Dates come only from SEC EDGAR and company announcements. Nothing here is investment advice.